glucose, (beta-d)-isomer has been researched along with B-Cell Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bessler, WG; Hoffmann, P; Körner, S; Müller, B; Pfannes, SD | 1 |
| Borisch, B; Hoessli, DC; Klages, N; Kulangara, K; Palomba, C; Semac, I; van Echten-Deckert, G | 1 |
2 other study(ies) available for glucose, (beta-d)-isomer and B-Cell Lymphoma
| Article | Year |
|---|---|
Induction of soluble antitumoral mediators by synthetic analogues of bacterial lipoprotein in bone marrow-derived macrophages from LPS-responder and -nonresponder mice.
Topics: Acridines; Animals; Bone Marrow Cells; Cytotoxicity, Immunologic; Drug Resistance; Enzyme Induction; Female; Free Radicals; Lipopolysaccharides; Lipoproteins; Luminescent Measurements; Lymphoma, B-Cell; Macrophage Activation; Macrophages; Male; Mast-Cell Sarcoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Reactive Oxygen Species; Respiratory Burst; Signal Transduction; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Zymosan | 2001 |
Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; beta-Cyclodextrins; CD55 Antigens; Cyclodextrins; Glucosides; Humans; Lymphoma, B-Cell; Membrane Lipids; Membrane Microdomains; Membrane Proteins; Phospholipase D; Phosphoproteins; Rituximab; src-Family Kinases; Type C Phospholipases | 2003 |